BridgeBio Pharma Gears Up for Noteworthy Investor Conferences
As a pioneering biopharmaceutical company committed to revolutionizing treatments for genetic diseases, BridgeBio Pharma, Inc. (NASDAQ: BBIO) is preparing to participate in several crucial healthcare investor conferences this upcoming November. With a strong focus on genetic medicine, the management team at BridgeBio will engage with investors, sharing insights about the company's innovative approach and research advancements.
Key Events on the Calendar
Members of BridgeBio's leadership will host fireside chats at two major conferences designed for healthcare investors:
UBS Global Healthcare Conference
The UBS Global Healthcare Conference, taking place on November 10, is a significant platform where BridgeBio's management will present alongside industry leaders. The fireside chat is scheduled for 1:15 PM EST, providing an opportunity for investors to engage in meaningful discussions about BridgeBio's pipeline and future directions.
Jefferies Global Healthcare Conference
Following the UBS conference, the Jefferies Global Healthcare Conference will occur in London on November 18. BridgeBio's management will be featured in a fireside chat at 11:00 AM EST, further showcasing the company's commitment to driving innovation in genetic therapies.
Accessing Presentations
For those interested in the discussions, BridgeBio invites stakeholders to access the live webcasts of their presentations. These will be available on the "Events and Presentations" section of the BridgeBio website. Additionally, a replay of these webcasts will be accessible for up to 90 days, ensuring that all interested parties can stay up-to-date with the latest company insights and developments.
Understanding BridgeBio Pharma, Inc.
Established to discover, create, and deliver transformative medicines, BridgeBio focuses on addressing the needs of patients suffering from genetic diseases. The company’s extensive development pipeline encompasses a broad array of programs, from foundational scientific research to advanced clinical trials. Since its founding in 2015, BridgeBio has assembled a team of industry veterans dedicated to advancing genetic medicine for the benefit of patients. Their mission is underscored by their commitment to swift advancements in treatment options.
Stay Connected with BridgeBio
BridgeBio is not only focused on developments in the lab but also emphasizes the importance of communication with its investors and stakeholders. For constant updates about their progress, investors can follow BridgeBio on various social media platforms, including LinkedIn, Twitter, Facebook, and Instagram. Engaging with the community is a vital component of their outreach and transparency initiatives.
BridgeBio Media and Investor Contacts
Media Inquiries:
Bubba Murarka, Executive Vice President, Corporate Development
Email: contact@bridgebio.com
(650)-789-8220
Investor Inquiries:
Chinmay Shukla, Senior Vice President, Strategic Finance
Email: ir@bridgebio.com
Frequently Asked Questions
What is BridgeBio Pharma focused on?
BridgeBio Pharma is dedicated to developing transformative therapies for patients with genetic diseases.
When will the investor conferences take place?
The UBS Global Healthcare Conference will be on November 10 and the Jefferies Global Healthcare Conference on November 18.
How can investors access the webcasts of the presentations?
Investors can visit the "Events and Presentations" page on the BridgeBio website to access live webcasts and replays.
What is BridgeBio's mission?
BridgeBio aims to discover, create, and deliver medicines that address the unmet needs of patients suffering from genetic diseases.
Who can be contacted for media inquiries?
Bubba Murarka, the Executive Vice President of Corporate Development, is the media contact for BridgeBio.
